Skip to main content
SpringerLink
Log in

The antiphospholipid-protein syndrome

  • Published:
Journal of Clinical Immunology Aims and scope Submit manuscript

Abstract

The pathogenesis of the antiphospholipid syndrome remains uncertain. Antibodies that react with phospholipids may not be directly responsible for cellular injury, but may be part of the immune network through which autoantibodies with pathogenic potential are generated. The latter may recognize proteins such asβ2-glycoprotein I that form complexes with phospholipids, proteins whose functions depend upon interaction with phospholipids such as protein C and its cofactors, altered lipoproteins such as oxidized low-density lipoproteins, or other molecules that share only antigenic similarity. Thus, a spectrum of autoantibodies that recognize different lipid-protein complexes may develop in these patients and contribute to the observed clinical heterogeneity of the syndrome. Current techniques do not permit identification of the subset of patients with antiphospholipid antibodies at risk for thrombosis or abortion and there are no prospective, controlled trials addressing the prophylaxis or treatment of affected individuals. Identification of the cellular targets of antibodies to lipid-protein moieties is needed to identify patients at risk for these complications and as a means to monitor therapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. McNeil HP, Chesterman CN, Krilis SA: Immunology and clinical importance of antiphospholipid antibodies. Adv Immunol 49:193–280, 1991

    PubMed  Google Scholar 

  2. Asherson R, Khamashta M, Ordi-Ros J, Derksen R, Machin S, Barquinero J, Out H, Harris E, Vilardell-Torres M, Hughes G: The “primary” antiphospholipid syndrome: major clinical and serologic features. Medicine 68:366–374, 1988

    Google Scholar 

  3. Love PE, Santoro SA: Antiphospholipid antibodies: Anticardiolipin and lupus anticoagulant in systemic lupus erythematosus (SLE) and non-SLE disorders. Ann Intern Med 112:682–698, 1990

    PubMed  Google Scholar 

  4. Gharavi AE, Harris EN, Asherson RA, Hughes GR: Anticardiolipin antibodies: Isotype distribution and phospholipid specificity. Ann Rheum Dis 46:1, 1987

    PubMed  Google Scholar 

  5. Devaux PF: Lipid transmembrane asymmetry and flip-flop in biological membranes and in lipid bilayers. Curr Opin Struct Biol 3:489–494, 1993

    Google Scholar 

  6. Schroit AJ, Zwaal RFA: Transbilayer movement of phospholipids in red cell and platelet membranes. BBA Rev Biomembr 1071: 313–329, 1991

    Google Scholar 

  7. Shi W, Chong BH, Chesterman CN:β2-Glycoprotein I is a requirement for anticardiolipin antibodies binding to activated platelets: Differences with lupus anticoagulants. Blood 81:1255–1262, 1993

    PubMed  Google Scholar 

  8. Galli M, Bevers EM, Comfurius P, Barbui T, Zwaal RFA: Effect of antiphospholipid antibodies on procoagulant activity of activated platelets and platelet-derived microvesicles. Br J Haematol 83:466–472, 1993

    PubMed  Google Scholar 

  9. Martinuzzo ME, Maclouf J, Carreras LO, Levy-Toledano S: Antiphospholipid antibodies enhance thrombin-induced platelet activation and thromboxane formation. Thromb Haemost 70:667–671, 1993

    PubMed  Google Scholar 

  10. Rauch J, Tannenbaum M, Tannenbaum H, Ramelson H, Cullis PR, Tilcock CPS, Hope MJ, Janoff AS: Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems. J Biol Chem 261:9672–9677, 1986

    PubMed  Google Scholar 

  11. Rauch J, Janoff AS: Phospholipid in the hexagonal II phase is immunogenic: Evidence for immunorecognition of nonbilayered lipid phasesin vivo. Proc Natl Acad Sci USA 87:4112–4114, 1990

    PubMed  Google Scholar 

  12. Schousboe I: Binding ofβ2-glycoprotein I to platelets: Effect of adenylate cyclase activity. Thromb Res 19:225–237, 1980

    PubMed  Google Scholar 

  13. Nimpf J, Bevers EM, Bomans PHH, Till U, Wurm H, Kostner GM, Zwaals RFA: Prothrombinase activity of human platelets in inhibited byβ2-glycoprotein-I. Biochim Biophys Acta 884:142–149, 1986

    PubMed  Google Scholar 

  14. Nimpf J, Wurm H, Kostner GM:β2-Glycoprotein-I (apo-H) inhibits the release reaction of human platelets during ADP-induced aggregation. Atherosclerosis 63:109–114, 1987

    PubMed  Google Scholar 

  15. Schousboe I:β2-glycoprotein I: A plasma inhibitor of the contact activation of intrinsic blood coagulation pathway. Blood 66: 1086–1091, 1985

    PubMed  Google Scholar 

  16. Galli M, Comfurius P, Maassen C, Hemker HC, DeBaets MH, Van Breda-Vriesman PJC, Barbui T, Zwaal RFA, Bevers EM: Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor. Lancet 335:1544–1547, 1990

    PubMed  Google Scholar 

  17. McNeil HP, Simpson RJ, Chesterman CN, Krillis SA: Anti-phospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation:β2-Glycoprotein I (apolipoprotein H). Proc Natl Acad Sci USA 87:4120–4125, 1990

    PubMed  Google Scholar 

  18. Steinkasserer A, Barlow PN, Willis AC, Kertesz Z, Campbell ID, Sim RB, Norman DG: Activity, disulphide mapping and structural modelling of the fifth domain of humanβ2-glycoprotein I. FEBS Lett 313:193–197, 1992

    PubMed  Google Scholar 

  19. Kouts S, Bunn CL, Steinkasserer A, Krilis S: Expression of human recombinantβ2-glycoprotein I with anticardiolipin anti-body cofactor activity. FASEB J 326:105–108, 1992

    Google Scholar 

  20. Hunt JE, Simpson RJ, Krilis SA: Identification of a region ofβ2-glycoprotein I critical for lipid binding and anti-cardiolipin antibody cofactor activity. Proc Natl Acad Sci USA 90:2141–2145, 1993

    PubMed  Google Scholar 

  21. Hunt J, Krilis S: The fifth domain ofβ2-glycoprotein I contains a phospholipid binding site (Cys281-Cys288) and a region recognized by anticardiolipin antibodies. J Immunol 152:653–659, 1994

    PubMed  Google Scholar 

  22. Arvieux J, Roussel B, Ponard D, Colomb MG: IgG2 subclass restriction on anti-β2 glycoprotein I antibodies in autoimmune patients. Clin Exp Immunol 95:310–315, 1994

    PubMed  Google Scholar 

  23. Matsuura E, Igarashi M, Igarashi Y, Nagae H, Ichikawa K, Yasuda T, Koike T: Molecular definition of humanβ2-glycoprotein I (β2-GPI) by cDNA cloning and inter-species differences ofβ2-GPI in alteration of anticardiolipin binding. Int Immunol 12:1217–1221, 1991

    Google Scholar 

  24. Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T: Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease. Lancet 366:177, 1990

    Google Scholar 

  25. Hunt JE, McNeil HP, Morgan GJ, Crameri RM, Krilis SA: A phospholipid-β2-glycoprotein I complex is an antigen for anticardiolipin antibodies occurring in autoimmune disease but not with infection. Lupus 1:75–81, 1992

    PubMed  Google Scholar 

  26. Roubey RAS, Pratt CW, Buyon JP, Winfield JB: Lupus anticoagulant activity of autoimmune antiphospholipid antibodies is dependent uponβ2-glycoprotein I. J Clin Invest 90:1100–1104, 1992

    PubMed  Google Scholar 

  27. Kra-Oz Z, Lorber M, Shoenfeld Y, Scharff Y: Inhibitor(s) of natural anti-cardiolipin autoantibodies. Clin Exp Immunol 93: 265–268, 1992

    Google Scholar 

  28. Rauch J, Tannenbaum M, Tannenbaum H, Ramelson H, Cullis PR, Tilcock CPS, Hope MJ, Janoff AS: Human hybridoma lupus anticoagulants distinguish between lamellar and hexagonal phase lipid systems. J Biol Chem 261:9672–9677, 1986

    PubMed  Google Scholar 

  29. Cabral AR, Cabiedes J, Alcaron-Segovia D, Sanchez-Guerrero J: Phospholipid specificity and requirement ofβ2-glycoprotein-I for reactivity of antibodies from patients with antiphospholipid syndrome. J Autoimmun 5:787–801, 1992

    PubMed  Google Scholar 

  30. Matsuda J, Saitoh N, Gochi K, Tsukamoto M, Nakamura K, Kinoshita T:β2-Glycoprotein I-dependent and -independent anticardiolipin antibody in patients with end-stage renal disease. Thromb Res 72:109–117, 1992

    Google Scholar 

  31. Arvieux J, Roussel B, Jacob MC, Colomb MG: Measurement of anti-phospholipid antibodies by ELISA usingβ2-glycoprotein I as an antigen. J Immunol Methods 143:223–229, 1991

    PubMed  Google Scholar 

  32. Gharavi AE: Antiphospholipid cofactor. Stroke 23 (Suppl I):I-7–I-10, 1992

    Google Scholar 

  33. Wagenknecht DR, McIntyre JA: Changes inβ2-glycoprotein I antigenicity induced by phospholipid binding. Thromb Haemost 69:361–365, 1993

    PubMed  Google Scholar 

  34. Matsuura E, Igarashi Y, Yasuda T, Triplett DA, Koike T: Anticardiolipin antibodies recognizeβ2-glycoprotein I structure altered by interacting with an oxygen modified solid phase surface. J Exp Med 179:457–462, 1994

    PubMed  Google Scholar 

  35. Lauer SA, Hempel U, Gries A, Frank K-H: Aminoacid sequence of the region ofβ2-glycoprotein 1 (gp1) which mediates binding of autoantibodies to the cardiolipin-gp1 complex in humans. Immunology 80:22–28, 1993

    PubMed  Google Scholar 

  36. Wagenknecht DR, McIntyre JA: Interaction of heparin withβ2-glycoprotein I and antiphospholipid antibodiesin vitro. Thromb Res 68:495–500, 1992

    PubMed  Google Scholar 

  37. Gharavi AE, Harris EN, Sammaritano LR, Pierangeli SS, Wen J: Do patients with antiphospholipid syndrome have autoantibodies toβ2-glycoprotein 1? J Lab Clin Med 122:426–431, 1993

    PubMed  Google Scholar 

  38. Bakimer R, Fishman P, Blank M, Sredni B, Djaldetti M, Shoenfeld Y: Induction of primary antiphospholipid syndrome in mice by immunization with a human monoclonal anticardiolipin antibody (H-3). J Clin Invest 89:1558–1563, 1992

    PubMed  Google Scholar 

  39. Villarreal GMD, Alcaron-Segovia D, Villa AR, Cabral AR, Shoenfeld Y: Presence of a 16/6-related human anti-DNA common idiotype (SA1) in the serum of patients with primary antiphospholipid syndrome. J Rheumatol 18:1537–1541, 1991

    PubMed  Google Scholar 

  40. Pierangeli SS, Harris EN: Induction of phospholipid-binding antibodies in mice and rabbits by immunization with humanβ2 glycoprotein I or anticardiolipin antibodies alone. Clin Exp Immunol 93:269–272, 1993

    PubMed  Google Scholar 

  41. Shi W, Chong BH, Hogg PJ, Chesterman CN: Anticardiolipin antibodies block the inhibition byβ2-glycoprotein I of the factor Xa generating activity of platelets. Thromb Haemost70:342–345, 1993

    PubMed  Google Scholar 

  42. Galli M, Comfurius P, Barbui T, Zwaal RFA, Bevers EM: Anticoagulant activity ofβ2-glycoprotein I is potentiated by a distinct subgroup of anticardiolipin antibodies. Thromb Haemost 68:297–300, 1992

    PubMed  Google Scholar 

  43. Brandt JT: Antibodies toβ2-glycoprotein I inhibit phospholipid dependent coagulation reactions. Thromb Haemost 70:598–602, 1993

    PubMed  Google Scholar 

  44. Matsuda J, Gochi K, Tsukamoto M, Saitoh N, Asami K, Hashimoto M: Anticoagulant activity of an anti-β2-glycoprotein I antibody is dependent on the presence ofβ2-glycoprotein I. Am J Hematol 44:187–191, 1993

    PubMed  Google Scholar 

  45. Hoeg JM, Segal P, Gregg RE, Chang YS, Lingren FT, Adamson GL, Frank M, Brickman C, Brewer Jr. HB: Characterization of plasma lipids and lipoproteins in patients withβ2-glycoprotein I (apolipoprotein H) deficiency. Atherosclerosis 55:25–34, 1985

    PubMed  Google Scholar 

  46. Bancsi LFMM, van der Linden IK, Bertina RM:β2-glycoprotein I deficiency and the risk of thrombosis. Thromb Haemost 67: 649–653, 1992

    PubMed  Google Scholar 

  47. Vermylen J, Amout J: Is the antiphospholipid syndrome caused by antibodies directed against physiologically relevant phospholipid-protein complexes? J Lab Clin Med 120:10–12, 1992

    PubMed  Google Scholar 

  48. Baja SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DB: A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 61: 684–691, 1983

    PubMed  Google Scholar 

  49. Edson JR, Vogt JM, Hasfawa DK: Abnormal prothrombin crossed-immunoelectrophoresis in patients with lupus inhibitors. Blood 64:807–817, 1984

    PubMed  Google Scholar 

  50. Fleck RA, Rappaport SI, Rao LVM: Anti-prothrombin antibodies and the lupus anticoagulant. Blood 72:512–519, 1988

    PubMed  Google Scholar 

  51. Berini JC, Buchanan GR, Ashcraft J: Hypoprothrombinemia and severe hemorrhage associated with a lupus anticoagulant. J Pediat 123:937–939, 1993

    PubMed  Google Scholar 

  52. Bevers EM, Galli M, Barbui T, Comfurius P, Zwaal RFA: Lupus anticoagulant IgGs (LA) are not directed to phospholipids only, but to a complex of lipid bound human prothrombin. Thromb Haemost 66:629–632, 1991

    PubMed  Google Scholar 

  53. Oosting JD, Derksen RHWM, Bobbink IWG, Hackeng TM, Bouma BN, De Groot PG: Antiphospholipid antibodies directed against a combination with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism? Blood 81:2618–2625, 1993

    PubMed  Google Scholar 

  54. Permpikul P, Rao, LVM, Rapaport SI: Functional and binding studies of the roles of prothrombin andβ 2-glycoprotein 1 in the expression of lupus anticoagulant activity. Blood 83:2878–2892, 1994

    PubMed  Google Scholar 

  55. McCrae KR, DeMichele A, Samuels P, Roth D, Kuo A, Meng Q-H, Rauch J, Cines DB: Detection of endothelial cell-reactive immunoglobulin in patients with anti-phospholipid antibodies. Br J Haematol 79:595–605, 1991

    PubMed  Google Scholar 

  56. McCrae KR, DeMichele AM, Baisai MJ, Samuels PS, Graham CH, Lala PK, Cines DB: Detection of anti-trophoblast antibodies in the sera of patients with anti-cardiolipin antibodies and fetal loss. Blood 82:2730–2741, 1993

    PubMed  Google Scholar 

  57. Skjonsberg OH, Wisloff F, Godal HC: Inhibition of the tissue factor-factor VII mediated activation of coagulation factor X by a monoclonal IgM antibody expressing lupus anticoagulant activity. Thromb Res 58:349–352, 1990

    PubMed  Google Scholar 

  58. Matsuda J, Saitoh N, Gohchi K, Gotoh M, Tsukamoto M: Anti-annexin V antibody in systemic lupus erythematosus patients with lupus anticoagulant and/or anticardiolipin antibody. Am J Hematol 47:56–58, 1994

    PubMed  Google Scholar 

  59. Vaaralo O, Alfthan G, Jauhianinen M, Leirisalo-Repo M, Aho K, Palosuo T: Crossreaction between antibodies to oxidized low-density lipoprotein and to cardiolipin in systemic lupus erythematosus. Lancet 341:923–925, 1993

    PubMed  Google Scholar 

  60. Ginsberg JS, Demers C, Brill-Edwards P, Johnston M, Bona R, Burrows RF, Weitz J, Denberg JA: Increased thrombin generation and activity in patients with systemic lupus erythematosus and anticardiolipin antibodies: Evidence for a prothrombotic state. Blood 81:2958–2963, 1993

    PubMed  Google Scholar 

  61. Le Roux G, Wautier M-P, Guillevin L, Wautier J-L: IgG binding to endothelial cells in systemic lupus erythematosus. Thromb Haemost 56:144–146, 1986

    PubMed  Google Scholar 

  62. Vismara A, Meroni PL, Tincani A, Harris EN, Barcellini W, Brucato A, Khamashta M, Hughes GRV, Zanussi C, Balestrieri G: Relationship between anti-cardiolipin and anti-endothelial cell antibodies in systemic lupus erythematosus. Clin Exp Immunol 74:247–253, 1988

    PubMed  Google Scholar 

  63. Walker TS, Triplett DA, Javed N, Musgrave K: Evaluation of lupus anticoagulants: Antiphospholipid antibodies, endothelium associated immunoglobulin, endothelial cell prostacyclin secretion, and antigenic protein S levels. Thromb Res 51:267–281, 1988

    PubMed  Google Scholar 

  64. Hasselaar P, Derksen RHWM, Blokzijl L, De Groot PG: Crossreactivity of antibodies directed against cardiolipin, DNA, endothelial cells and blood platelets. Thromb Haemost 63:169–173, 1990

    PubMed  Google Scholar 

  65. Cervera R, Khamashta MA, Font J, Ramirez G, D'Cruz D, Montalban J, Lopez-Soto A, Asherson RA, Ingelmo M, Hughes GRV: Antiendothelial cell antibodies in patients with the antiphospholipid syndrome. Autoimmunity 11:1–6, 1991

    PubMed  Google Scholar 

  66. Del Papa N, Meroni PL, Tincani A, Harris EN, Pierangeli SS, Bareelllni W, Borghi MO, Balestrieri G, Zanussi C: Relationship between anti-phospholipid and anti-endothelial cell antibodies: Further characterization of the reactivity on resting and cytokine-activated endothelial cells. Clin Exp Rheumatol 10:37–42, 1992

    PubMed  Google Scholar 

  67. McCrae KR, Cines DB: Immunologic properties of antibodies to endothelial cells: Relationship to antiphospholipid antibodies.In Antibodies to Endothelial Cells and Vascular Damage, R Cervera, MA Khamashta, GRV Hughes (eds). Boca Raton, FL, CRC Press, 1994, pp 47–69

    Google Scholar 

  68. Alegre VA, Winkelmann RK: Histopathologic and immunofluorescence study of skin lesions associated with circulating lupus anticoagulant. J Am Acad Dermatol 19:117–124, 1988

    PubMed  Google Scholar 

  69. Carreras LO, Vermylen JG: “Lupus” anticoagulant and thrombosis—Possible role of inhibition of prostacyclin formation. Thromb Haemost 48:38–40, 1982

    PubMed  Google Scholar 

  70. Watson KV, Schorer AE: Lupus anticoagulant inhibition ofin vitro prostacyclin release is associated with a thrombosis-prone subset of patients. Am J Med 90:47–53, 1991

    PubMed  Google Scholar 

  71. Schorer AE, Duane PG, Woods VL, Niewoehner DE: Some antiphospholipid antibodies inhibit phospholipase A2 activity. J Lab Clin Med 120:67–77, 1992

    PubMed  Google Scholar 

  72. Lellouche F, Martinuzzo M, Said P, Maclouf J, Carreras LO: Imbalance of thromboxane/prostacyclin biosynthesis in patients with lupus anticoagulant. Blood 78:2894–2899, 1991

    PubMed  Google Scholar 

  73. Orlando E, Cortelazzo S, Marchetti M, Sanfratello R, Barbui T: Prolonged bleeding time in patients with lupus anticoagulant. Thromb Haemost 68:495–499, 1992

    PubMed  Google Scholar 

  74. Hasselaar P, Derksen RHM, Blokzijl L, De Groot PG: Thrombosis associated with antiphospholipid antibodies cannot be explained by effects on endothelial cell and platelet prostanoid synthesis. Thromb Haemost 59:80–85, 1988

    PubMed  Google Scholar 

  75. Cariou R, Tobelem G, Bellucci S, Soria J, Soria C, Maclouf J, Caen J: Effect of lupus anticoagulant on antithrombogenic properties of endothelial cells—Inhibition of thrombomodulin-dependent protein C activation. Thromb Haemost 60:54–58, 1988

    PubMed  Google Scholar 

  76. Francis Jr. RB, McGehee WG, Feinstein DI: Endothelial-dependent fibrinolysis in subjects with the lupus anticoagulant and thrombosis. Thromb Haemost 59:412–414, 1988

    PubMed  Google Scholar 

  77. Tsakiris DA, Marbet GA, Makris PE, Settas L, Duckert F: Impaired fibrinolysis as an essential contribution to thrombosis in patients with lupus anticoagulant. Thromb Haemost 61:175–177, 1989

    PubMed  Google Scholar 

  78. Francis Jr. RB, Neely S: Effect of the lupus anticoagulant on endothelial cell fibrinolytic activityin vitro. Thromb Haemost 61:314–317, 1989

    PubMed  Google Scholar 

  79. Keeling DM, Campbell SJ, Mackie IJ, Machin SJ, Isenberg DA: The fibrinolytic response to venous occlusion and the natural anticoagulants in patients with antiphospholipid antibodies both with and without systemic lupus erythematosus. Br J Haematol 77:354–359, 1991

    PubMed  Google Scholar 

  80. Jurado M, Paramo JA, Gutierrez-Pimental M, Rocha E: Fibrinolytic potential and antiphospholipid antibodies in systemic lupus erythematosus and other connective tissue disorders. Thromb Haemost 68:516–520, 1992

    PubMed  Google Scholar 

  81. Cosgriff TM, Martin BA: Low functional and high antigenic antithrombin III level in a patient with the lupus anticoagulant and recurrent thrombosis. Arth Rheum 24:94–96, 1981

    Google Scholar 

  82. Chamley LW, McKay EJ, Pattison NS: Inhibition of heparinantithrombin III cofactor activity by anticardiolipin antibodies: A mechanism for thrombosis. Thromb Res 71:103–111, 1993

    PubMed  Google Scholar 

  83. Lo SCL, Salem HH, Howard MA, Oldmeadow MJ, Firkin BG: Studies of natural anticoagulant proteins and anticardiolipin antibodies in patients with the lupus anticoagulant. Br J Haematol 76:380–386, 1990

    PubMed  Google Scholar 

  84. Killeen AA, Meyer KC, Vogt JM, Edson JR: Kallikrein inhibition and C1-esterase inhibitor levels in patients with the lupus inhibitor. Am J Clin Pathol 88:223–228, 1988

    Google Scholar 

  85. Sanfelippo MJ, Drayna CJ: Prekallikrein inhibition associated with the lupus anticoagulant. Am J Clin Pathol 77:275–279, 1982

    PubMed  Google Scholar 

  86. Hasselaar P, Derksen RHWM, Oosting JD, Blokzijl L, de Groot PG: Synergistic effect of low doses of tumor necrosis factor and sera from patients with systemic lupus erythematosus on the expression of procoagulant activity by cultured endothelial cells. Thromb Haemost 62:654–660, 1989

    PubMed  Google Scholar 

  87. Rustin MHA, Bull HA, Machin SJ, Isenberg DA, Snaith ML, Dowd PM: Effects of the lupus anticoagulant in patients with systemic lupus erythematosus on endothelial cell prostacyclin release and procoagulant activity. J Invest Dermatol 90:744–748, 1988

    PubMed  Google Scholar 

  88. Oosting JD, Derksen RHWM, Blokzikl L, Sixma JJ, De Groot PG: Antiphospholipid antibody positive sera enhance endothelial cell procoagulant activity—Studies in a thrombosis model. Thromb Haemost 68:278–284, 1992

    PubMed  Google Scholar 

  89. Branch DW, Rodgers GM: Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: A possible mechanism of thrombosis. Am J Obstet Gynecol 168:206–210, 1993

    PubMed  Google Scholar 

  90. Kornberg A, Blank M, Kaufman S, Jchoenfeld Y: Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol 153:1328–1332, 1994

    PubMed  Google Scholar 

  91. Silver RK, Adler L, Hickman AR, Hageman JR: Anticardiolipin antibody-positive serum enhances endothelial cell platelet activating factor production. Am J Obstetr Gynecol 165:1748–1752, 1991

    Google Scholar 

  92. Sammaritano LR, Gharavi AE, Soberano C, Levy RA, Lockshin MD: Phospholipid binding of antiphospholipid syndrome and placental anticoagulant protein. J Clin Immunol 12:27–35, 1992

    PubMed  Google Scholar 

  93. Rand JH, Wu X, Guller S, Scher J, Lockwood CJ: Antiphospholipid antibodies reduce immunohistochemically detectable annexin-V (placental anticoagulant protein-I) on the surfaces of placental villiin vitro. Blood 82(S):404a, 1993 (abstract)

    Google Scholar 

  94. Comp PC, DeBault LE, Esmon NL, Esmon CT: Human thrombomodulin is inhibited by IgG from two patients with non-specific anticoagulants. Blood 62(S):2990, 1983 (abstract)

    Google Scholar 

  95. Freyssinet J-M, Wiesel M-L, Gauchy J, Boneu B, Cazenave J-P: An IgM lupus anticoagulant that neutralizes the enhancing effect of phospholipid on purified endothelial thrombomodulin activity. A mechanism for thrombosis. Thromb Haemost 55:309–313, 1986

    PubMed  Google Scholar 

  96. Toyoshima K, Makino T, Ozawa N, Umeuchi M, Nozawa S: Effect of anticardiolipin antibody in patients with recurrent fetal loss on thrombomodulin-dependent protein C activation. J Clin Lab Anal 7:57–59, 1993

    PubMed  Google Scholar 

  97. Ruiz-Arguelles GJ, Ruiz-Arguelles A, Deleze M, Alarcon-Segovia D: Acquired protein C deficiency in a patient with primary antiphospholipid syndrome. Relationship to activity and anticardiolipin antibody with thrombomodulin. J Rheumatol 16: 381–383, 1989

    PubMed  Google Scholar 

  98. Gibson J, Nelson M, Brown R, Salem H, Kronenberg H: Autoantibodies to thrombomodulin: Development of an enzyme immunoassay and a survey of their frequency in patients with the lupus anticoagulant. Thromb Haemost 67:507–509, 1992

    PubMed  Google Scholar 

  99. Ruiz-Arguelles A, Vasquez-Prado J, Deleze M, Perez-Romano B, Brenkard C, Alcaron-Segovia D, Ruiz-Arguelles GJ: Presence of serum antibodies to coagulation protein C in patients with systemic lupus erythematosus is not associated with antigenic or functional protein C deficiencies. Am J Hematol 44:58–59, 1993

    PubMed  Google Scholar 

  100. Friedman KD, Marlar RA, Gill JC, Endres-Brooks J, Montgomery RR: Protein S deficiency in patients with the lupus anticoagulant. Blood 68(S):6330, 1986 (abstract)

    Google Scholar 

  101. Tsakiris DA, Settas L, Makris PE, Marbet GA: Lupus anticoagulant antiphospholipid antibodies and thrombophilia. Relation to protein C-protein S-thrombomodulin. J Rheumatol 17:785–789, 1990

    PubMed  Google Scholar 

  102. Ruiz-Arguelles GJ, Ruiz-Arguelles A, Alcaron-Segovia D, Drenkard C, Villa A, Cabiedes J, Prenso-Bernal M, Deleze M, Ortiz-Lopez R, Vazquez-Prado J: Natural anticoagulants in systemic lupus arythematosus. Deficiency of protein S bound to C4bp associated with recent history of venous thrombosis, antiphospholipid antibodies and the antiphospholipid syndrome. J Rheumatol 18:552–558, 1991

    PubMed  Google Scholar 

  103. Ruiz-Arguelles GJ, Ruiz-Arguelles A, Perez-Romano B, Alarcon-Segovia D: Protein S deficiency associated with antiprotein S antibodies in a patient with mixed connective-tissue disease and its reversal by danazol. Acta Haematol 89:206–208, 1993

    PubMed  Google Scholar 

  104. Moreb J, Kitchens CS: Acquired functional protein S deficiency, cerebral venous thrombosis, and coumarin skin necrosis in association with antiphospholipid syndrome: Report of two cases. Am J Med 87:207–210, 1989

    PubMed  Google Scholar 

  105. Parke AL, Weinstein RE, Bona RD, Maier DB, Walker FJ: The thrombotic diathesis associated with the presence of phospholipid antibodies may be due to low levels of free protein S. Am J Med 93:49–56, 1992

    PubMed  Google Scholar 

  106. Stahl CP, Wideman CS, Spira TJ, Haff EC, Hixon GJ, Evatt BL: Protein S deficiency in men with long-term human immunodeficiency virus infection. Blood 81:1801–1807, 1993

    PubMed  Google Scholar 

  107. Rossi E, Gatti L, Guarneri D, Finotto E, Lombardi A, Preda L: Functional protein S in women with lupus anticoagulant inhibitor. Thromb Res 65:253–262, 1992

    PubMed  Google Scholar 

  108. D'Angelo AD, Crippa L, D'Angelo SV: Autoimmune protein S deficiency. N Engl J Med 328:1898, 1993

    Google Scholar 

  109. Keeling DM, Campbell SJ, Mackie IJ, Machin SJ, Isenberg DA: Total and free protein S in systemic lupus erythematosus. Thromb Res 60:237–240, 1990

    PubMed  Google Scholar 

  110. Marciniak E, Romond EH: Impaired catalytic function of activated protein C: A newin vitro manifestation of lupus anticoagulant. Blood 74:2426–2432, 1989

    PubMed  Google Scholar 

  111. Amer L, Kisiel W, Searles RP, Williams Jr RC: Impairment of the protein C anticoagulant pathway in a patient with systemic lupus erythematosus, anticardiolipin antibodies and thrombosis. Thromb Res 57:247–258, 1990

    PubMed  Google Scholar 

  112. Malia RG, Kitchen S, Greaves M, Preston FE: Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies. Br J Haematol 76:101–107, 1990

    PubMed  Google Scholar 

  113. Borrell M, Sala N, de Castellarnau C, Lopez S, Gari M, Fontcuberta J: Immunoglobulin fractions isolated from patients with antiphospholipid antibodies prevent the inactivation of factor Va by activated protein C on human endothelial cells. Thromb Haemost 68:268–272, 1992

    PubMed  Google Scholar 

  114. Dahlbuck, B. Physiological anticoagulation. Resistance to activated protein C and venous thromboembolism. J Clin Invest 94:923–927, 1994

    PubMed  Google Scholar 

  115. Oosting JD, Derksen RHWM, Hackeng TM, Van Vliet M, Preissner KT, Bouma BN, Groot De PG:In vitro studies of antiphospholipid antibodies and its cofactor,β2-glycoprotein I, show negligible effects on endothelial cell mediated protein C activation. Thromb Haemost 66:666–671, 1992

    Google Scholar 

  116. Asano T, Furie BC, Furie B: Platelet binding properties of monoclonal lupus autoantibodies produced by human hybridomas. Blood 66:1254–1260, 1985

    PubMed  Google Scholar 

  117. Rauch J, Meng Q-H, Tannenbaum H: Lupus anticoagulant and antiplatelet properties of human hybridoma autoantibodies. J Immunol 139:2598–2604, 1987

    PubMed  Google Scholar 

  118. Murakami H, Lam Z, Furie BC, Reinhold VN, Asano T, Furie B: Sulfated glycolipids are the platelet autoantigens for human platelet-binding monoclonal anti-DNA autoantibodies. J Biol Chem 266:15414–15419, 1991

    PubMed  Google Scholar 

  119. Khamashta MA, Harris EN, Gharavi AE, Derue G, Gil A, Vasquez JJ, Hughes GRV: Immune mediated mechanism for thrombosis: Antiphospholipid antibody binding to platelet membranes. Ann Rheum Dis 47:849–854, 1988

    PubMed  Google Scholar 

  120. Dahlback B, Nilsson IM, Frohm B: Inhibition of platelet prothrombinase activity by a lupus anticoagulant. Blood 62:218–225, 1983

    PubMed  Google Scholar 

  121. Galli M, Beguin S, Lindhout T, Hemker HC: Inhibition of phospholipid and platelet-dependent prothrombinase activity in the plasma of patients with lupus anticoagulants. Br J Haematol 72:549–555, 1989

    PubMed  Google Scholar 

  122. Out HJ, De Groot PG, Van Vliet M, de Gast GC, Nieuwenhuis HK, Derksen RHWM: Antibodies to platelets in patients with anti-phospholipid antibodies. Blood 77:2655–2659, 1991

    PubMed  Google Scholar 

  123. Vázquez-Mellado J, Llorente L, Richaud-Patin Y, Alcarón-Segovia O: Exposure of anionic phospholipids upon platelet activation permits binding ofβ 2 glycoprotein 1 and through it that of IgG antiphospholipid antibodies. Studies in platelets from patients with antiphospholipid syndrome and normal subjects. J Autoimmun 7:335–348, 1994

    PubMed  Google Scholar 

  124. Nomura S, Yanubo M, Fukuroi T, Kido H, Kawakatsu T, Yamaguchi K, Suzuki M, Kokawa T, Yasunaga K: Antiphospholipid antibodies bind to platelet microparticles in idiopathic (autoimmune) thrombocytopenic purpura. Ann Hematol 65:46–49, 1992

    PubMed  Google Scholar 

  125. Ichikawa Y, Kobayashi N, Kawada T, Shimizu H, Moriuchi J, Ono H, Watanabe K, Arimori S: Reactivities of anti-phospholipid antibodies to blood cells and their effects on platelet aggregationin vitro. Clin Exp Rheumatol 8:461–468, 1990

    PubMed  Google Scholar 

  126. Escolar G, Font J, Reverter JC, Lopez-Soto A, Garrido M, Cervera R, Ingelmo M, Castillo R, Ordinas A: Plasma from systemic lupus erythematosus patients with antiphospholipid antibodies promotes platelet aggregation. Studies in a perfusion system. Arterioscler Thromb 12:196–200, 1992

    PubMed  Google Scholar 

  127. Schorer AE, Wickham NWR, Watson KV: Lupus anticoagulant induces a selective defect in thrombin-mediated endothelial cell prostacyclin release and platelet aggregation. Br J Haematol 71:399–407, 1989

    PubMed  Google Scholar 

  128. Goldsmith GH, Pierangeli SS, Branch DW, Gharavi AE, Harris EN: Inhibition of prothrombin activation by antiphospholipid antibodies andβ 2 glycoprotein 1. Br J Hematolol 87:548–554, 1994

    Google Scholar 

  129. Biasiolo A, Pengo V: Antiphospholipid antibodies are not present in the membrane of gel-filtered platelets of patients with IgG anticardiolipin antibodies, lupus anticoagulant and thrombosis. Blood Coag Fibrinol 4:425–428, 1993

    Google Scholar 

  130. Alarcon-Segovia D, Sanchez-Guerrero J: Correction of thrombocytopenia with small dose aspirin in the primary antiphospholipid syndrome. J Rheumatol 16:1359–1361, 1989

    PubMed  Google Scholar 

  131. De Wolf F, Carreras LO, Moerman P, Vermylen J, Van Assche A, Renaer M: Decidual vasculopathy and extensive placental infarction in a patient with repeated thromboembolic accidents, recurrent fetal loss and a lupus anticoagulant. Am J Obstet Gynecol 142:829–834, 1982

    PubMed  Google Scholar 

  132. Out HJ, Kooijman CD, Bruinse HW, Derksen RHWM: Histopathological findings in placentae from patients with intrauterine fetal death and anti-phospholipid antibodies. Eur J Obstet Gynecol Reprod Biol 41:179–186, 1991

    PubMed  Google Scholar 

  133. Branch DW, Dudley DJ, Mitchell MD, Creighton KA, Abbott TM, Hammond EH, Daynes RA: Immunoglobulin G fractions from patients with antiphospholipid antibodies cause fetal death in Balb/C mice: A model for autoimmune fetal loss. Am J Obstet Gynecol 163:210–216, 1990

    PubMed  Google Scholar 

  134. Blank M, Cohen J, Toder V, Shoenfeld Y: Induction of antiphospholipid syndrome in naive mice with mouse lupus monoclonal and human polyclonal anti-cardiolipin antibodies. Proc Natl Acad Sci USA 88:3069–3073, 1991

    PubMed  Google Scholar 

  135. Guzman L, Avalos E, Ortiz R, Gurrola R, Lopez E, Herrera R: Placental abnormalities in systemic lupus erythematosus:In situ deposition of antinuclear antibodies. J Rheumatol 14:924–929, 1987

    PubMed  Google Scholar 

  136. Krause I, Blank M, Gilbruit B, Shoenfeld Y: The effect of aspirin on recurrent fetal loss in experimental antiphospholipid syndrome. Am J Reprod Immunol 29:155–161, 1993

    PubMed  Google Scholar 

  137. Inbar O, Blank M, Faden D, Tincani A, Lorber M, Shoenfeld Y: Prevention of fetal loss in experimental antiphospholipid syndrome by low-molecular weight heparin. Am J Obstet Gynecol 169:423–426, 1993

    PubMed  Google Scholar 

  138. Bakimer R, Guilburd B, Zurgil N, Shoenfeld Y: The effect of intravenous γ-globulin on the induction of experimental antiphospholipid syndrome. Clin Immunol Immunopathol 69:97–102, 1993

    PubMed  Google Scholar 

  139. Fishman P, Falach-Vaknine E, Zigelman R, Bakimer R, Sredni B, Djaldetti M, Shoenfeld Y: Prevention of fetal loss in experimental antiphospholipid syndrome byin vivo administration of recombinant interleukin-3. J Clin Invest 91:1834–1837, 1993

    PubMed  Google Scholar 

  140. Chamley LW, Pattison NS, McKay ET: Elution of anticardiolipin antibodies and their cofactorβ 2-glycoprotein 1 from the placentae of patients with a poor obstetric history. J Reprod Immunol 25:209–220, 1993

    PubMed  Google Scholar 

  141. Hasegawa I, Takakuwa K, Adachi S, Kanazawa K: Cytotoxic antibody against trophoblast and lymphocytes present in pregnancy with intrauterine fetal growth retardation and its relation to anti-phospholipid antibody. J Reprod Immunol 17:127–139, 1990

    PubMed  Google Scholar 

  142. Peaceman AM, Rehnberg BA: The immunoglobulin G fraction from plasma containing antiphospholipid antibodies causes increased placental thromboxane production. Am J Obstet Gynecol 167:1543–1547, 1992

    PubMed  Google Scholar 

  143. Tulpappa M, Viinikka L, Ylikorkala O: Thromboxane dominance and prostacyclin deficiency in habitual abortion. Lancet 337:879–881, 1991

    PubMed  Google Scholar 

  144. Zini JM, Murray SC, Graham CH, Lala PK, Barnathan ES, Mazar A, Henkin J, Cines DB, McCrae KR: Characterization of urokinase receptor expression by human placental trophoblasts. Blood 79:2917–2929, 1992

    PubMed  Google Scholar 

  145. Shurtz-Swirski R, Inbar O, Blanck M, Cohen J, Bakimer R, Barnea ER, Shoenfeld Y:In vitro effect of anticardiolipin autoantibodies upon total and pulsatile placental HCG secretion during early pregnancy. Am J Reprod Immunol 29:206–210, 1993

    PubMed  Google Scholar 

  146. Gleicher N, Harlow L, Zilberstein M: Regulatory effect of antiphospholipid antibodies on signal transduction: A possible model for autoantibody-induced reproductive failure. Am J Obstet Gynecol 167:637–542, 1992

    PubMed  Google Scholar 

  147. Vila P, Hernández MC, López-Fernandez MF, Batille J: Prevalence, follow-up, and clinical significance of the anticardiolipin antibodies in normal subjects. Thromb Haemost 72:209–213, 1994

    PubMed  Google Scholar 

  148. Ginsburg KS, Liang MH, Newcomer L, Goldhaber SZ, Shur PH, Hennekens CH, Sampfer MJ: Anticardiolipin antibodies and the risk for ischemic stroke and venous thrombosis. Ann Intern Med 117:997–1002, 1992

    PubMed  Google Scholar 

  149. Ghirardello A, Doria A, Ruffatti A, Rigoli AM, Vesco P, Calligaro A, Gambari PF: Antiphospholipid antibodies (aPL) in systemic lupus erythematosus. Are they specific tools for the diagnosis of aPL syndrome? Ann Rheum Dis 53:140–142, 1994

    PubMed  Google Scholar 

  150. The Antiphospholipid Antibodies in Stroke Study (APSS) Group: Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. Neurology 43:2069–2073, 1993

    Google Scholar 

  151. Tietjen GE, Levine SR, Brown E, Mascha E, Welch KMA: Factors that predict antiphospholipid immunoreactivity in young people with transient neurologic events. Arch Neurol 50:833–836, 1993

    PubMed  Google Scholar 

  152. Brey RL, Hart RG, Sherman DG, Tegeler CH: Antiphospholipid antibodies and cerebral ischemia in young people. Neurology 40:1190–1196, 1990

    PubMed  Google Scholar 

  153. Braune S, Siekmann R, Vaith P, Lucking CH: Primary antiphospholipid antibody syndrome and cerebral ischemia: report on acute intervention in two cases and literature review with emphasis on therapeutic options. Rheumatol Internal 13:169–174, 1993

    Google Scholar 

  154. Nencini P, Baruffi MC, Abbate R, Massai G, Amaducci L, Inzitari D: Lupus anticoagulant and anticardiolipin antibodies in young adults with cerebral ischemia. Stroke 23:189–193, 1992

    PubMed  Google Scholar 

  155. Levine SR, Deegan MJ, Futrell N, Welch KMA: Cerebrovascular and neurologic disease associated with antiphospholipid antibodies: 48 cases. Neurology 40:1181–1189, 1990

    PubMed  Google Scholar 

  156. Asherson RA, Chan JKH, Harris EN, Gharavi AE, Hughes GRV: Anticardiolipin antibody, recurrent thrombosis, and warfarin withdrawal. Ann Rheum Dis 44:823–825, 1985

    PubMed  Google Scholar 

  157. Asherson RA, Baguley E, Pal C, Hughes GRV: Antiphospholipid syndrome: Five year follow up. Ann Rheum Dis 50:805–810, 1991

    PubMed  Google Scholar 

  158. Derksen RHWM, deGroot PG, Nieuwenhuis HK: Patients with antiphospholipid antibodies and venous thrombosis should receive long term anticoagulant treatment. Ann Rheum Dis 52: 689–692, 1993

    PubMed  Google Scholar 

  159. Gris JC, Schved JF, Tousch D, Hereil S, Feugeas O: Antiidiotypic antibodies against anti-phospholipid autoantibodies which suppress lupus-like anticoagulant activity. Nouv Rev Fr Hematol 30:143–147, 1988

    PubMed  Google Scholar 

  160. Galli M, Cortelazzo S, Barbui T:In vivo efficacy of intravenous gammaglobulins in patients with lupus anticoagulant is not mediated by an anti-idiotypic mechanism. Am J Hematol 38: 184–188, 1991

    PubMed  Google Scholar 

  161. Said PB, Martinuzzo ME, Carreras LO: Neutralization of lupus anticoagulant activity by human immunoglobulin “invitro.” Nouv Rev Fr Hematol 34:37–42, 1992

    PubMed  Google Scholar 

  162. Matsuda J, Gochi K, Kawasugi K, Tsukamoto M, Saitoh N, Kinoshita T:In vitro lupus anticoagulant neutralizing activity of intravenous immunoglobulin. Thromb Res 70:109–110, 1993

    PubMed  Google Scholar 

  163. Wapner RJ, Cowchock FS, Shapiro SS: Successful treatment in two women with antiphospholipid antibodies and refractory pregnancy losses with intravenous immunoglobulin infusions. Am J Obstet Gynecol 161:1271–1272, 1989

    PubMed  Google Scholar 

  164. Carreras LO, Perez GN, Vega HR, Casavilla F: Lupus anticoagulant and recurrent fetal loss: Successful treatment with gammaglobulin. Lancet 2:393, 1988

    Google Scholar 

  165. Scott JR, Branch DW, Kochenour NK, Ward K: Intravenous immunoglobulin treatment of pregnant patients with recurrent pregnancy loss caused by antiphospholipid antibodies and Rh immunization. Am J Obstet Gynecol 159:1055–1056, 1988

    PubMed  Google Scholar 

  166. McVerry BA, Spearing R, Smith A: SLE anticoagulant: Transient inhibition by high dose immunoglobulin infusions. Br J Haematol 61:579–580, 1985

    PubMed  Google Scholar 

  167. Carreras LO, Perez GN, Martinuzzo ME, Malan-Borel I, Malbran A, Said PB: Partial neutralization of a lupus anticoagulant by human immunoglobulin. Thromb Haemost 64:32–37, 1990

    PubMed  Google Scholar 

  168. Parke A, Maier D, Wilson D, Andreoli J, Ballow M: Intravenous gamma-globulin, antiphospholipid antibodies, and pregnancy. Ann Intern Med 110:495–496, 1991

    Google Scholar 

  169. Branch DW, Silver RM, Blackwell JL, Reading JC, Scott JR: Outcome of treated pregnancies in women with antiphospholipid syndrome: An update of the Utah experience. Obstetr Gynecol 80:614–629, 1992

    Google Scholar 

  170. Christiansen OB, Mathiesen O, Lauritsen JG, Grunnet N: Intravenous immunoglobulin treatment of women with multiple miscarriages. Hum Reprod 7:718–722, 1992

    PubMed  Google Scholar 

  171. Sturfelt G, Mousa F, Jonsson H, Nived O, Thyssel H, Wollheim F: Recurrent cerebral infarction and the antiphospholipid syndrome: Effect of intravenous gammaglobulin in a patient with systemic lupus erythematosus. Ann Rheum Dis 49:939–941, 1990

    PubMed  Google Scholar 

  172. Elias M, Eldor A: Thromboembolism in patients with the “lupus”-type circulating anticoagulant. Arch Intern Med 144: 510–515, 1984

    PubMed  Google Scholar 

  173. Lockwood CJ, Romero R, Feinberg RF, Clyne LP, Coster B, Hobbins JC: The prevalence and biologic significance of lupus anticoagulant and anticardiolipin antibodies in a general obstetric population. Am J Obstet Gynecol 161:369–373, 1989

    PubMed  Google Scholar 

  174. Out HJ, Bruinse HW, Derksen RHWM: Antiphospholipid antibodies and pregnancy loss. Hum Reprod 6:889–897, 1991

    PubMed  Google Scholar 

  175. Lynch A, Marlar M, Murphy J, Davila G, Santos M, Rutledge J, Emlen W: Antiphospholipid antibodies in predicting adverse pregnancy outcome. A prospective study. Ann Intern Med 120: 470–475, 1994

    PubMed  Google Scholar 

  176. Harris EN, Spinnato JA: Should anticardiolipin tests be performed in otherwise healthy women? Am J Obstet Gynecol 165:1272–1277, 1991

    PubMed  Google Scholar 

  177. Infante-Rivard C, David M, Gauthier R, Rivard G-E: Lupus anticoagulants, anticardiolipin antibodies, and fetal loss. A casecontrol study. N Engl J Med 325:1063–1066, 1991

    PubMed  Google Scholar 

  178. Petri M, Allbritton J: Fetal outcome of lupus pregnancy: A retrospective case-control study of the Hopkins lupus cohort. J Rheumatol 20:650–656, 1993

    PubMed  Google Scholar 

  179. Ginsberg JS, Brill-Edwards P, Johnston M, Denburg JA, Andrew M, Burrows RF, Bensen W, Cividino A, Long AA: Relationship of antiphospholipid antibodies to pregnancy loss in patients with systemic lupus erythematosus: A cross-sectional study. Blood 80:975–980, 1992

    PubMed  Google Scholar 

  180. Out HJ, Bruinse HW, Christiaens GCML, Van Vliet M, Meilof JF, De Groot PG, Smeenk RJT, Derksen RHWM: Prevalence of antiphospholipid antibodies in patients with fetal loss. Ann Rheum Dis 50:553–557, 1991

    PubMed  Google Scholar 

  181. Out HJ, Bruinse HW, Godelieve MD, Christiaens CML, Van Vliet M, De Groot PG, Niuewenhuis HK, Derksen RHWM: A prospective, controlled multicenter study on the obstetric risks of pregnant women with antiphospholipid antibodies. Am J Obstet Gynecol 167:26–32, 1992

    PubMed  Google Scholar 

  182. Harger JH, Archer DF, Marchese SG, Muracca-Clemens M, Garver KL: Etiology of recurrent pregnancy losses and outcome of subsequent pregnancies. Obstetr Gynecol 62:574–581, 1983

    Google Scholar 

  183. Parke AL, Wilson D, Maier D: The prevalence of antiphospholipid antibodies in women with recurrent spontaneous abortions, women with successful pregnancies, and women who have never been pregnant. Arth Rheum 34:1231–1235, 1991

    Google Scholar 

  184. Stray-Pedersen B, Stray-Pedersen S: Etiologic factors and subsequent reproductive performance in 195 couples with a prior history of habitual abortion. Am J Obstet Gynecol 148:140–146, 1984

    PubMed  Google Scholar 

  185. Viaanderen W, Treffers PE: Prognosis of subsequent pregnancies after recurrent spontaneous abortion in the first trimester. Br Med J 295:92–93, 1987

    Google Scholar 

  186. Lockshin MD, Druzin ML, Qamar T: Prednisone does not prevent fetal death in women with antiphospholipid antibodies. Am J Obstet Gynecol 160:439–443, 1989

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Pathology and Laboratory Medicine, 7 Founders Pavilion, Hospital of the University of Pennsylvania, 3400 Spruce Street, 19104, Philadelphia, Pennsylvania

    Douglas B. Cines

  2. Sol Sherry Thrombosis Research Center, Temple University School of Medicine, 3400 North Broad Street, 19104, Philadelphia, Pennsylvania

    Keith R. McCrae

Authors
  1. Douglas B. Cines
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Keith R. McCrae
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cines, D.B., McCrae, K.R. The antiphospholipid-protein syndrome. J Clin Immunol 15 (Suppl 6), S86–S100 (1995). https://doi.org/10.1007/BF01540898

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01540898

Key words

Search

Navigation